Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests

Nicolas R Barthélemy, Gemma Salvadó, Suzanne Schindler, Yingxin He, Shorena Janelidze, Lyduine E Collij, Benjamin Saef, Rachel L Henson, Charles D Chen, Brian A Gordon, Yan Li, Renaud La Joie, Tammie L S Benzinger, John C Morris, Niklas Mattsson-Carlgren, Sebastian Palmqvist, Rik Ossenkoppele, Gil D Rabinovici, Erik Stomrud, Randall J BatemanOskar Hansson

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

Sammanfattning

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. We evaluated whether a precise blood test could perform as well as established cerebrospinal fluid (CSF) tests in detecting amyloid-β (Aβ) plaques and tau tangles. Plasma %p-tau217 (ratio of phosporylated-tau217 to non-phosphorylated tau) was analyzed by mass spectrometry in the Swedish BioFINDER-2 cohort (n=1,422) and the US Knight ADRC cohort (n=337). Matched CSF samples were analyzed with clinically used and FDA-approved automated immunoassays for Aβ42/40 and p-tau181/Aβ42. The primary and secondary outcomes were detection of brain Aβ or tau pathology, respectively, using PET imaging as the reference standard. Main analyses were focused on individuals with cognitive impairment (mild cognitive impairment and mild dementia), which is the target population for available disease-modifying treatments. Plasma %p-tau217 was clinically equivalent to FDA-approved CSF tests in classifying Aβ PET status, with an area-under-the-curve (AUC) for both between 0.95-0.97. Plasma %p-tau217 was generally superior to CSF tests in classification of tau-PET with AUCs of 0.95-0.98. In cognitively impaired sub-cohorts (BioFINDER-2: n=720; Knight ADRC: n=50), plasma %p-tau217 had an accuracy, positive predictive value and negative predictive value of 89-90% for Aβ PET and 87-88% for tau-PET status, which was clinically equivalent to CSF tests, further improving to 95% using a two cut-off approach. Blood plasma %p-tau217 demonstrated performance clinically equivalent or superior to clinically used FDA-approved CSF tests in the detection of AD pathology. Use of high performance blood tests in clinical practice can improve access to accurate AD diagnosis and AD-specific treatments.

Originalspråkengelska
Antal sidor42
TidskriftNature Medicine
DOI
StatusE-pub ahead of print - 2024 feb. 21

Ämnesklassifikation (UKÄ)

  • Neurologi
  • Neurovetenskaper

Fingeravtryck

Utforska forskningsämnen för ”Highly Accurate Blood Test for Alzheimer's Disease Comparable or Superior to Clinical CSF Tests”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här